Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Kymera Therapeutics Inc | KYMR | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 33.62 | 03:09:40 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 33.62 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 9.60 - 45.31 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 33.62 | USD |
Kymera Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.05B | 61.11M | - | 78.59M | -146.96M | -2.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kymera Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KYMR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 35.66 | 36.47 | 32.75 | 33.91 | 505,074 | -2.04 | -5.72% |
| 1 Month | 37.27 | 38.09 | 32.75 | 35.11 | 502,599 | -3.65 | -9.79% |
| 3 Months | 34.30 | 45.31 | 32.75 | 38.63 | 624,978 | -0.68 | -1.98% |
| 6 Months | 11.48 | 45.31 | 9.60 | 29.36 | 800,313 | 22.14 | 192.86% |
| 1 Year | 31.48 | 45.31 | 9.60 | 25.84 | 665,900 | 2.14 | 6.80% |
| 3 Years | 45.79 | 69.12 | 9.60 | 31.39 | 578,128 | -12.17 | -26.58% |
| 5 Years | 32.92 | 91.92 | 9.60 | 32.89 | 514,552 | 0.70 | 2.13% |
Kymera Therapeutics Description
| Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients. |
